NewsRoom Articles - Page 169 of 233

WednesdayJul 28, 2021 10:36 am

Researchers Discover New Phase in Stem Cell Cycle That May Help Develop Tumor Treatments

Researchers from Arizona State University are conducting a study on the life cycle of stem cells. The study may be useful in the development of new techniques for treating brain cancer. The research was reported in the “Molecular Systems Biology” journal. Assistant professor of biomedical engineering from the institution’s school of engineering Christopher Plaisier stated that the research team had discovered a new phase in the cycle during their study. This new information was discovered through an alliance with associate professor Patrick Paddison from the Fred Hutchinson Cancer Research Center and University of Washington’s assistant professor of neurological surgery Dr.…

WednesdayJul 28, 2021 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is ‘One to Watch’

MINDCURE’s proprietary digital therapeutics technology platform creates a high barrier to entry for any potential competitors The company maintains active partnerships with growing firms in AI, technology, and mental health MINDCURE’s world-class scientific discovery team has decades of combined experience in researching and commercializing pharmaceutical grade drugs The company has demonstrated a clear path to near-term revenues and boasts a strong financial position Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing…

WednesdayJul 28, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable the evaluation of patient outcomes Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy. “The digital therapeutics platform, which is proprietary to Cybin and the…

TuesdayJul 27, 2021 1:30 pm

Danish Researchers Discover That Medical Marijuana May Combat Essential Tremor

There is huge debate on what medicinal properties, if any, marijuana possesses, and researchers are working to uncover the effects of this substance. For example, a team of researchers from the University of Copenhagen in Denmark has discovered that medical marijuana has the ability to reduce involuntary shaking or essential tremor. Their research used a mouse model. The team’s work focused on a synthetic cannabinoid WIN55.212-2. The scientists found that when the mice were injected with this cannabinoid, astrocytes or support cells found within the brain and spinal cord of the mice were activated. When those support cells are activated,…

MondayJul 26, 2021 10:00 am

Post-Op Immunotherapy May Lower Risk of Bladder Cancer Recurrence

A new study conducted by researchers from the Memorial Sloan Kettering Cancer Center has discovered that after undergoing bladder removal operations, the risk of high-grade bladder cancer recurrence decreased after the nivolumab formulation was administered to patients. Together with a group of researchers, Dr. Dean Bajorin, who is a medical oncologist at the institute, evaluated more than 700 patients who had a high risk of urothelial cancer recurring after their kidney, ureter or bladder had been removed because of advanced metastatic bladder cancer. Urothelial cancers are tumors that develop in the muscle lining of the urinary system. These cancers are…

FridayJul 23, 2021 12:00 pm

Researchers Compare COVID-19 to Other Respiratory Ailments

A group of researchers from the United States and Israel conducted a study that compared the disease progression and presentation between in-hospital patients suffering from COVID-19 with other respiratory ailments such as influenza. They discovered that coronavirus patients displayed a unique cardiorespiratory, immune and metabolic profile, noting that the disease’s severity was higher in comparison with other respiratory illnesses. The virus that causes the coronavirus, SARS-CoV-2, is a deadly and highly infectious virus. It has infected more than 190 million individuals and claimed more than 4 million lives across the globe, despite the effective control measures that were implemented in…

ThursdayJul 22, 2021 12:17 pm

Study Finds That Focusing on the Past May Worsen Symptoms of Depression

A study recently published in the “Journal of Psychiatric Research” discovered that childhood trauma was linked to higher symptoms of depression, particularly in individuals who demonstrated a tendency to focus on the past instead of the future or even the present. Clinical depression, which is also known as major depressive disorder, is among the most common mental health conditions in the world. Childhood trauma is a typical feature of the disorder. The authors of the stud — Yingying Wang and colleagues — suggest that a personality factor may play a role in this association between depression and early trauma, noting…

ThursdayJul 22, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event

Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the…

WednesdayJul 21, 2021 2:34 pm

Teasing About Weight Could Trigger Eating Disorders

Prior studies have discovered that young individuals who experience discrimination or teasing about their weight have higher rates of eating disorders, self-harm, depression and social isolation. However, these studies have primarily focused on high-income and white participants, which makes it unclear whether these findings apply to other groups as well. This is why researchers from the School of Public Health at the University of Minnesota in Minneapolis conducted a study to examine the link between eating disorders and weight stigma in a socioeconomically and racially/ethnically diverse sample of more than 1,500 young individuals in the United States. An eating disorder…

WednesdayJul 21, 2021 9:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Begin Patient Dosing in Berubicin Phase 2 Clinical Trial During Q3 2021, and Received Fast Track Designation from FDA

CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the…